Chronic human immunodeficiency virus type 1 (HIV-1) infection is associated with induction of T-cell coinhibitory pathways. However, the mechanisms by which HIV-1 induces upregulation of coinhibitory molecules remain to be fully elucidated. The aim of the present study was to determine whether and how HIV-1 Tat protein, an immunosuppressive viral factor, induces the PD-1/PD-L1 coinhibitory pathway on human dendritic cells (DCs). We found that treatment of DCs with whole HIV-1 Tat 
H
uman immunodeficiency virus type 1 (HIV-1) infection is characterized by a multitude of complex interactions between the virus and its host immune system (1) . Starting from the acute phase, HIV-1 infection establishes a peak of virus replication, followed by a severe and rapid depletion of CD4 ϩ T cells in the lymphoid tissues (2) . In addition to CD4 ϩ T cells, HIV-1 also targets and infects monocytes, macrophages, and, to a lesser level, dendritic cells (DCs), leading to the weakening of the host's immune responses to infection. DCs, the main antigen-presenting cells (APC), play key roles in both innate and adaptive immune responses (3) (4) (5) . Interactions between HIV-1 and the DCs lead to immune activation starting from the acute phase of infection (6, 7) . This immune activation, which persists throughout the chronic phase of infection, is associated with gradual depletion of circulating CD4
ϩ T cells and increased exhaustion of T cells associated with a high set point of viral replication (8) (9) (10) (11) . This persists despite an increase in T-cell turnover (12) , a decrease in plasmacytoid DC (pDC) (13) and myeloid DC (mDC) numbers (14) , and increased production of proinflammatory cytokines and chemokines (15, 16) . Consequently, this leads inevitably to a further weakening of the immune system, a situation that facilitates HIV-1 replication and persistence and leads to fast progression to AIDS (8) (9) (10) (11) .
HIV-1 infection is also associated with upregulation of the PD-1/PD-L1 immunosuppressive pathway, but the viral factors and mechanisms by which HIV-1 may induce upregulation of these coinhibitory molecules on DCs remain to be fully elucidated.
PD-L1 and PD-L2 ligands share several domains, characteristic of the B7 immunoglobulin family (17, 18) . Several pathogens that lead to chronic or persistent infections, including lymphocytic choriomeningitis virus (LCMV) (19) , simian immunodeficiency virus (SIV) (20) , HIV-1 (21-23), hepatitis B virus (HBV) (24) , human T-cell leukemia (HTLV) (22) , hepatitis C virus (HCV) (25) , and herpes simplex virus (HSV) (26, 27) , have been reported to induce the PD-1/PD-L1 coinhibitory pathway as an immune evasion mechanism, often associated with the functional exhaustion (i.e., dysfunction) of virus-specific CD4 ϩ and CD8 ϩ T cells (28) .
Blockade of PD-1/PD-L1 interaction has been shown, both in vitro and in vivo, to reverse the exhaustion and restore the function of T cells (29) (30) (31) (32) . Although HIV-1 has been reported to use many T-cell coinhibitory pathways, including PD-1/PD-L1, to evade control by the immune system, the viral factors by which HIV-1 induces upregulation of many T-cell coinhibitory molecules remain to be fully elucidated.
It has been reported that, among the viral factors, Tat protein interferes with the normal function of the immune system (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) . HIV-1 Tat is a protein of 14 kDa, composed of 86 to 104 amino acids (aa), that is produced early after HIV-1 infection (41) . At the structural level, Tat protein is structured in several domains, including the N-terminal region of aa 1 to 47 which contains the activation domain and the basic region of aa 49 to 57, which is essential for Tat internalization, nuclear localization, and RNA binding at the long terminal repeat (LTR)-TAR region (41) . In addition to its essential role in the viral cycle, Tat protein is found at nanomolar (nM) levels in the sera of HIV-1-infected patients (44) (45) (46) . However, it can reasonably be assumed that this quantification of Tat protein is underestimated, given the amount of Tat already adsorbed on the surface of cell membranes via heparan sulfates (47) and because this concentration is much larger near the lymphoid organs and in the vicinity of infected cells than in the sera (48) .
Tat protein participates in the pathogenesis of HIV-1 infection by its capacity to interact with different cell types (48) . It is secreted by infected cells and can act on neighboring immune cells whether they are infected or not (34, 49) . In addition to its direct role in viral promoter trans activation of transcription, Tat also contributes indirectly to the spread of HIV-1 through an increase of the rate of CCR5 and CXCR4 cell surface expressions (50, 51) and through the activation of quiescent CD4 ϩ T cells, which in turn are used by the virus as new targets to enhance HIV-1 replication (52) . Tat has also been found to induce neurotoxicity in the central nervous system (53) (54) (55) and apoptosis in CD4 ϩ T cells (45, 56, 57) .
While some of the above-given effects were mediated following intracellular uptake of Tat, others were mediated by the extracellular interaction of Tat with specific cellular receptors (48) . Different domains of Tat can interact with specific membrane receptors, including the CD26 receptor (58) , the CXCR4 chemokine receptor (46) , the L-type calcium channel (59) , integrin ␣v␤3 and ␣5␤1 of DCs (60) , membrane lipids (55) , and the Flk-1/KDR receptor (61) . In addition to these potential Tat receptors, we have recently demonstrated that Tat protein is able to recruit the Tolllike receptor 4 (TLR4) pathway, following its interaction with high affinity with TLR4-MD2 complex, to activate the production of proinflammatory tumor necrosis factor alpha (TNF-␣) and antiinflammatory interleukin 10 (IL-10) cytokines (62) .
The aims of the study presented here were (i) to explore the potential effect of HIV-1 Tat protein on the upregulation of PD-1, PD-L1, and PD-L2 coinhibitory molecules on the surface of MoDCs and (ii) to understand the underlying molecular mechanisms by which HIV-1 Tat would affect the phenotypic and functional expression of these coinhibitory molecules. The results show that the HIV-1 Tat protein specifically induced the upregulation of PD-L1 (also known as B7-H1) on MoDCs through an indirect mechanism involving TNF-␣ and TLR4 pathways.
MATERIALS AND METHODS
Recombinant and synthetic proteins. HIV-1 Tat recombinant protein (aa 1 to 86) from the HIV-1 Lai strain was obtained from the Agence Nationale de la Recherche sur le SIDA (ANRS; Paris, France). HIV-1 Tat protein from the SF2 strain (Tat aa 1 to 101) or N-terminal Tat fragments (Tat aa 1 to 45) fused to glutathione S-transferase (GST) were produced and purified in our laboratory as previously described (33) . Chemically synthesized Tat (aa 1 to 86) protein from the HIV-1 Lai strain and the oxidized form of Tat were produced as described by Vives et al. (63) . The level of endotoxin in all these recombinant proteins was assessed using the Limulus amebocyte lysate assay (Bio-Sepra, Villeneuve la Garenne, France) and was shown to be below 0.3 EU/g, the limit of detection of this test.
Chemical products. Lipopolysaccharide (LPS), from Escherichia coli serotype R515, was purchased from Alexis Biochemicals. Pam3CSK4 (TLR1/2 ligand) was purchased from Invitrogen.
Recombinant cytokines and antibodies. Recombinant human cytokines TNF-␣, IL-10, IL-6, and gamma interferon (IFN-␥) were purchased from eBioscience. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 were purchased from HumanZyme. Recombinant murine GM-CSF was purchased from Tebu Bio. Mouse monoclonal anti-human TNF-␣ (TNF-D), anti-TLR4/MD2 (HTA 125), and mouse IgG isotype control antibodies were purchased from eBioscience. Anti-Tat antibodies were obtained from ANRS. Polyclonal goat anti-human IFN-␥ and monoclonal mouse anti-human IL-10 (clone number 25209) were purchased from R&D Systems. For cell surface labeling, fluorochrome-conjugated antibodies anti-CD1a-fluorescein isothiocyanate (FITC) (HI149), anti-CD14-phycoerythrin (PE) (HCD14), anti-CD80-FITC (2D10), anti-CD83-FITC (HB15e), anti-CD86-PE (IT2.2), anti-HLA-DR-FITC (L243), anti-mouse CD86-PE (PO3), and isotype control were purchased from BioLegend. Anti-human CD1c-FITC (AD5-8E7) was purchased from Miltenyi Biotech. Anti-PD-1-APC (eBioJ105), anti-PD-L1-APC (MIH1), anti-PD-L2-PE (MIH18), anti-mouse PD-L1-PE (MIH5), and isotype controls were purchased from eBioscience.
Generation of monocyte-derived DCs. Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy blood donors (from Etablissement Français du Sang [EFS], Toulouse) or from blood samples of HIV-1-infected patients who were under effective antiretroviral treatment (from the Department of Infectious Diseases of Toulouse University Hospital) by centrifugation on Ficoll-Paque density gradient (GE Healthcare). Monocytes were isolated by adherence to tissue culture plastic on 6-well plates (Becton Dickinson) after 1 h at 37°C and 5% CO 2 . Nonadherent cells were removed, and adherent cells were washed three times with PBS. This adherent population was CD14 ϩ (Ͼ94%) when analyzed by flow cytometry. To allow their differentiation into monocyte-derived DCs (MoDCs), cells were cultured in RPMI medium (Invitrogen) supplemented with 10% fetal calf serum (FCS) (Invitrogen), 100 IU/ml penicillin, 100 g/ml streptomycin, 10 ng/ml GM-CSF, and 10 ng/ml IL-4. Alternatively, monocytes were isolated by positive selection using a CD14 ϩ isolation kit (Myltenyi Biotec). After 5 days of culture, loosely adherent cells were recovered by gentle pipetting and used as immature DCs in our experiments. Over 90% of cells had the standard phenotype of immature DCs:
Isolation of primary human myeloid DCs. Primary myeloid DCs were isolated from human PBMCs by negative selection, using the myeloid dendritic cell isolation kit, according to the manufacturer's instructions (Miltenyi Biotec). The isolated DCs were characterized by the ex-pression of a CD1c (BDCA-1) marker. The purity of the isolated CD1c ϩ DCs was Ͼ95%, as determined by flow cytometry.
Generation of bone marrow-derived DCs. The C57BL/6 mice were obtained from Charles River Laboratory. TLR4-knockout (KO) mice with a C57BL/6 genetic background were kindly provided by the laboratory of B. Ryffel (INEM, UMR7355 CNRS-University of Orleans, France). Myeloid cells were extracted from the bone marrow of mouse femur by being washed with 5 ml of complete RPMI 1640, using a syringe. After homogenization, filtration, and centrifugation (5 min at 20°C and 1,200 rpm), the cell suspension was recovered in 10 ml of complete RPMI 1640 medium. To stimulate the differentiation into DCs, myeloid cells were cultured in 100-by 20-mm petri dishes (Dominique Dutscher) at 2 ϫ 10 6 cells in 10 ml of complete RPMI 1640 medium in the presence of 50 ng/ml of recombinant murine GM-CSF. The medium was renewed after 3 and 6 days of culture. Bone marrow-derived DCs (BMDCs) were recovered in the supernatant after 9 days of culture and used as immature cells.
Treatment of DCs. Immature MoDCs or BMDCs were resuspended in RPMI complete medium and distributed in 6-, 12-, or 24-well plates at a density of 1 ϫ 10 6 cells/ml and then treated for 24 h or for the indicated time. Then, cells were recovered and analyzed for the expression of surface molecules by flow cytometry. Cell culture supernatants were collected and kept frozen until cytokine quantification.
To obtain Tat-conditioned medium, MoDCs or BMDCs were treated with Tat for 1 h, washed three times with PBS to remove soluble Tat, and then cultured for a further 24 h. After this time, the cell supernatant was recovered, centrifuged for 10 min at 1,200 rpm, and used as Tat-conditioned medium to stimulate autologous cells.
In the transwell experiment, untreated MoDCs were cultured in 6-well plates (Becton, Dickinson). In the upper chamber of the 1-m transwell insert, we added autologous MoDCs previously incubated with Tat for 1 h and washed three times with PBS. Cells were kept in coculture for a further 24 h before they were separately analyzed for the expression of surface molecules by flow cytometry.
In the direct coculture experiment, MoDCs previously treated with Tat for 1 h and washed were mixed with autologous Tat-untreated carboxyfluorescein succinimidyl ester (CFSE)-labeled MoDCs. After 24 h of incubation, MoDCs were recovered and the phenotype was analyzed in CFSE-labeled and CFSE-unlabeled cells using different windows, gating on a FACSCalibur (Becton, Dickinson).
Phenotype analysis by flow cytometry. For flow cytometry analysis, MoDCs were first washed once with PBS and 5 mM EDTA and then once with PBS and 5% FCS. Cells were then incubated cold for 30 min with fluorochrome-conjugated antibodies. After 2 washes with PBS-5% FCS, cells were recovered in PBS-0.01% azide before analysis on a FACSCalibur.
Cytokine quantifications. Quantification of TNF-␣, IL-10, IL-6, IFN-␣1, IL-12p70, and IFN-␥ in cell supernatants was performed with a specific ELISA kit from eBioscience. Briefly, the first monoclonal antibody used for capture was incubated overnight at 4°C in 96 wells (Nunc). After three washes with PBS containing 0.05% Tween 20, pH 7.4 (wash buffer), plates were saturated by adding 250 l of a protein solution (diluent assay) for 1 h at room temperature. After three washes, culture supernatants (100 l/well) were added and incubated for 2 h at room temperature. Plates were then washed three times and incubated for 1 h at room temperature with a biotinylated anticytokine antibody. After five washes, the bound biotinylated antibody was detected by an additional 30 min of incubation with streptavidin peroxidase. After seven washes, plates were incubated with the enzyme substrate (3,3=,5,5=-tetramethylbenzidine [TMB]). The reaction was stopped by adding 50 l of H 2 SO 4 (2N) to each well. Absorbance was read at 450 nm with a wavelength correction at 570 nm. Cytokines were quantified from a standard curve generated by using various concentrations of recombinant protein of each cytokine. The limit of detection of each cytokine was 4 pg/ml for TNF-␣, 2 pg/ml for IL-10, 2 pg/ml for IL-6, 15 pg/ml for IFN-␣, 4 pg/ml for IFN-␥, and 4 pg/ml for IL-12p70.
Effect of PD-L1 upregulation on T-cell proliferation. Peripheral blood lymphocytes (PBLs) were isolated as a nonadherent cell, or CD14-negative untouched cell, fraction from PBMCs. After labeling with CFSE (2 M) using the CellTrace CFSE proliferation kit (Invitrogen), labeled PBLs were cocultured with autologous MoDCs, previously treated with synthetic Tat (50 nM) or GST-recombinant proteins (100 nM) in the presence or absence of anti-PD-L1 antibodies (MIH1) at 10 g/ml. As a control, the same isotype IgGs were used. MoDCs (2 ϫ 
RESULTS

HIV-1 Tat protein induced phenotypic maturation of monocyte-derived dendritic cells. HIV-1 infection is associated with an
increase of immunosuppressive factors such as IL-10 (64), PD-1/ PD-L1 T-cell coinhibitory pathway (65) , and IDO (66), which in turn leads to establishment of an immunosuppressive state. Since HIV-1 Tat protein, used in either recombinant or synthetic form, has been (i) portrayed as an immunosuppressive factor by several reports, including ours (33, 40, (67) (68) (69) (70) , and (ii) shown to affect DC maturation (37, 71) , it was of interest to determine whether HIV-1 Tat would also lead to induction of the maturation marker (CD83) or costimulatory (CD80 and CD86) and coinhibitory (PD-1/PD-L1/PD-L2) molecules on DCs.
To this end, using flow cytometry (fluorescence-activated cell sorting [FACS]), we first monitored the expression of CD80 and CD86 costimulatory molecules and CD83 maturation marker (here designated maturation markers) on MoDCs following 24 h of incubation with either recombinant or chemically synthetic forms of HIV-1 Tat protein. We showed that monocyte-derived dendritic cells expressed the expected immature DC markers CD1a ϩ , CD14 Ϫ , CD80 low , CD86 low , CD83 Ϫ , and HLA-DR ϩ (Fig.  1 ). As shown in Fig. 1a to c, incubation of immature MoDCs with HIV-1 Tat protein resulted in the acquisition of a phenotype characteristic of mature DCs, as determined by a significant increase in the level of expression of DC maturation markers (CD83, CD80, and CD86) compared to the relatively low levels expressed on untreated immature MoDCs (Fig. 1a) . As a negative control, MoDCs treated similarly with the same amount of a recombinant GST protein did not show any significant increase in the level of expression of maturation markers ( Fig. 1a to c) . Moreover, we showed that synthetic reduced Tat protein, but not its oxidized form, stimulated CD86 expression in a dose-dependent manner ( Fig. 1b and c) . As expected, MoDCs treated with LPS (positive control) showed a significant increase in the expression level of all maturation markers (Fig. 1a) .
To demonstrate the specificity of Tat action, we showed that treatment with previously heated Tat protein completely abrogated its capacity to induce MoDC phenotypic maturation, while treatment with heated LPS had no effect on its capacity to activate MoDC maturation (Fig. 1a) . Cumulative data obtained from 10 independent experiments indicated that Tat induced a significant and reproducible upregulation of CD80, CD83, and CD86 maturation markers in MoDCs obtained from 10 different donors. A significant increase of the mean fluorescence intensity (MFI) was observed for MoDCs of all donors after 24 h of treatment with Tat (P Ͻ 0.001; Fig. 1d to i) .
All together, these results indicate that HIV-1 Tat induced phenotypic maturation of MoDCs by stimulating cell surface expression of CD83, CD80, and CD86 maturation markers.
HIV-1 Tat protein induced expression of the PD-L1 coinhibitory molecule on DCs. We next determined the effect of HIV-1 Tat protein on the expression of coinhibitory molecules, including PD-1, PD-L1, and PD-L2, on MoDCs. To this end, MoDCs were treated for 24 h with HIV-1 Tat protein, and the levels of the PD-1, PD-L1, and PD-L2 molecules expressed on the cell surface were determined by FACS, as described above. At steady state, immature MoDCs expressed a significant level of PD-L1 molecules on the cell surface compared to the levels of PD-1 and PD-L2 molecules, which were relatively low (Fig. 2a,  Untreated) . Incubation of immature MoDCs with GST-Tat led to a strong upregulation of PD-L1 on the cell surface (Fig. 2a , GSTTat). In contrast, no effect on the expression of PD-L2 and PD-1 molecules on MoDCs was detected following treatment in the same conditions by GST-Tat protein (Fig. 2a, GST-Tat) . No significant change in PD-L1 expression was detected on MoDCs treated in the same conditions by GST alone as a negative control (Fig. 2a and c, GST) . In addition, we showed that synthetic reduced Tat protein, but not its oxidized form, modulated PD-L1 upregulation ( Fig. 2d and e) . Considering these results, we focused our study on the modulation of the PD-L1 coinhibitory molecule by Tat protein.
We found that (i) in escalating-dose experiments, recombinant or synthetic Tat proteins stimulated PD-L1 expression in a dose-dependent manner (Fig. 2b, d , and e), (ii) heat treatment of Tat protein totally abolished its effect on PD-L1 expression on MoDCs, while the same treatment on LPS had no effect on its capacity to upregulate PD-L1 expression (Fig. 2c, middle) , (iii) the effect of Tat protein on the expression of PD-L1 on MoDCs was totally abrogated in the presence of anti-Tat antibodies (Fig. 2c,  right) , (iv) SH-reduced chemically synthetic Tat protein, but not its oxidized form, stimulated PD-L1 upregulation on MoDCs, suggesting the importance of at least one SH-free group in this biological activity of Tat (Fig. 2d and e) , (vi) PD-L1 upregulation was induced by Tat proteins from both the Lai and SF2 strains, indicating that the effect on PD-L1 was conserved at least in these two HIV-1 isolates (Fig. 2a, c, and d) .
To determine whether the effect of HIV-1 Tat on the expression of PD-L1 can be generalized, we tested the effect of Tat protein on MoDCs derived from 10 different HIV-1-seronegative donors of various ages and both genders. As shown in Fig. 2f and g, the stimulation of PD-L1 expression induced by Tat protein was detected on MoDCs from each donor regardless of age or gender. Although the level of expression of PD-L1 varied among donors, a significant increase of the MFI was observed for all donors, with a mean ranging from 46 in untreated MoDCs to 352 in Tat-treated MoDCs (P Ͻ 0.001; Fig. 2f and g ).
To address the effect of Tat protein on PD-L1 expression in a more physiological setting, we explored its effect on primary human myeloid DCs. To this ends, myeloid DCs were purified by negative selection from the PBMCs of four healthy donors. Analysis by flow cytometry of isolated cells confirmed their positivity for the CD1c marker. Interestingly, the treatment of primary myeloid DCs with Tat protein led to a significant upregulation of PD-L1 expression on DCs from each of the four donors (P Ͻ 0.01; Fig. 3a to c) . This upregulation was observed for myeloid DCs of each donor starting 24 h after treatment with Tat ( Fig. 3c) and was statistically significant (P Ͻ 0.01; Fig. 3b ). Furthermore, we also explored this phenomenon in a pathological setting using DCs isolated from HIV-1-infected patients. However, for practical considerations, due to the rarity of peripheral blood myeloid DCs in HIV-1-infected patients, as an alternative, we tested the effect of Tat on MoDCs derived from three HIV-1-infected patients that were under effective antiretroviral treatments. The results confirmed that Tat continued to significantly stimulate PD-L1 expression even on MoDCs from HIV-1-infected patients ( Fig. 3d and f ; P Ͻ 0.05).
HIV-1 Tat protein induces PD-L1 expression on MoDCs through its N-terminal fragment.
In order to evaluate the mechanism by which HIV-1 Tat stimulates PD-L1 expression on MoDCs, in addition to the whole GST-Tat 1-101 protein, we produced a truncated GST N-terminal fragment of Tat that was unable to trans activate HIV-1 LTR: the N-terminal 1-45 fragment. As expected, the small truncated GST N-terminal 1-45 fragment (i) migrated faster on the SDS-PAGE gel than the whole GST-Tat 1-101 protein (Fig. 4a) and (ii) was detected by antibodies specific either to Tat protein or to the GST-tagged region. In contrast, the GST-tagged region was detected by anti-GST antibodies but not by anti-Tat protein antibodies (Fig. 4a) . As expected, unlike the whole GST-Tat 1-101 protein, the truncated GST N-terminal 1-45 fragment was unable to stimulate trans activation of the HIV-1 LTR, as assessed by its incapacity to activate the gene of ␤-galactosidase (␤-Gal) under the control of the HIV-1 LTR (Fig. 4b) .
At a functional level, we found that like the whole GST-Tat 1-101 protein, the truncated GST N-terminal 1-45 fragment was also able to stimulate the upregulation of PD-L1, but not PD-L2, on MoDCs, as detected by FACS (Fig. 4c and d) .
All together, these results suggest that the observed effect of HIV-1 Tat on PD-L1 upregulation on MoDCs can be mapped to Tat upregulates PD-L1 expression on MoDCs through an indirect mechanism. To assess whether the effect of Tat protein required direct interaction between Tat and MoDCs or acted indirectly through a secondary factor, we conducted the following coculture experiment. MoDCs were treated with Tat for 1 h, washed three times with PBS, and then cocultured, at a 1:1 ratio, with autologous Tat-untreated MoDCs. To identify Tat-treated and -untreated MoDCs from the same culture, only Tat-untreated MoDCs were prelabeled with CFSE (1 M). After 24 h of coculture, the level of PD-L1 expression was determined on CFSE ϩ and CFSE Ϫ MoDCs. After the flow plots were gated on CFSE ϩ and CFSE Ϫ MoDCs, the flow cytometry analysis showed that preincubation with Tat protein induced PD-L1 upregulation on both Tattreated CFSE Ϫ and untreated CFSE ϩ MoDCs in a dose-dependent manner ( Fig. 5a and b) . As a control, we showed that CFSE ϩ and CFSE Ϫ MoDCs expressed similar basal levels of PD-L1 in the absence of Tat stimulation (Fig. 5a and b) . In addition, we showed that CFSE labeling had no effects on cell viability, as demonstrated by the capacity of Tat to continue to upregulate PD-L1 in a manner similar to that in non-CFSE-labeled MoDCs (Fig. 5a and b) . This result suggests that Tat protein acts on PD-L1 modulation by an indirect mechanism through induction of a secondary factor, which could be soluble or membrane associated.
The induction of PD-L1 expression on MoDCs by HIV-1 Tat protein does not require direct cell-cell contact but is rather mediated by soluble factor(s).
To understand the mode of action of Tat (via soluble or membrane-associated factors), we tested whether PD-L1 upregulation on MoDCs can occur without direct cell-cell contact through a soluble factor that might be released by Tat-treated MoDCs. To this end, this experiment was done in two steps: (i) following 1 h of treatment of MoDCs with Tat, the cells were washed to eliminate any residual soluble Tat protein; (ii) the Tat-treated MoDCs and untreated MoDCs were then cultured in two different compartments separated by a microporous membrane that allowed soluble factors to diffuse between the upper and lower compartments (known as the transwell coculture system). After an additional 24 h of coculture, MoDCs from each compartment were harvested and the level of PD-L1 expression on their cell surface was determined using FACS. Interestingly, in addition to the expected PD-L1 upregulation on Tat-treated MoDCs from the upper chamber, a significant upregulation of PD-L1 molecules was also detected on the MoDCs from the lower chamber, which had never been in direct contact with Tat protein (Fig. 6a and b) . In agreement with the latter data, we also showed that Tat-conditioned medium obtained from the supernatants of MoDCs previously treated with Tat protein for 24 h was sufficient to induce the upregulation of PD-L1 on immature MoDCs in the absence of direct Tat treatment (Fig. 7a and b) . These results indicate that the effect of Tat protein on PD-L1expression is independent of Tat-cell or cell-cell contacts and suggests that the effect is mediated indirectly through yet-to-be-determined soluble factors or cytokines.
Therefore, in the next key kinetic experiment, we determined whether and when PD-L1 optimal expression on MoDCs coincided with production of the major Tat-induced cytokines, including TNF-␣, IL-10, IL-12, IL-6, IFN-␣, and IFN-␥ cytokines. This strategy allowed the cytokines that are produced with later kinetics than PD-L1 expression to be excluded, as those cytokines may not be involved in the mechanisms of PD-L1 upregulation. As shown in (Fig. 6c to i) , MoDCs that were directly treated with Tat protein exhibited PD-L1 upregulation in a time-dependent manner, as was also observed for cytokine induction. Specifically, upregulation of PD-L1 resumed 6 h after treatment of MoDCs with Tat protein (Fig. 6c) . Maximum upregulation of PD-L1 was reached around 24 h poststimulation and was followed by a plateau of expression (Fig. 6c) . Among the panel of six Tat-induced cytokines (Fig. 6d to i) , we tested only TNF-␣, IL-10, and IL-6, cytokines that were produced before 6 h (i.e., before PD-L1 expression was resumed following Tat stimulation; Fig. 6c) .
These results suggest that TNF-␣, IL-10, and IL-6 cytokines may be involved in a mechanism that leads to upregulation of PD-L1 on MoDCs following Tat treatment. However, because exogenous recombinant IL-6 failed to upregulate PD-L1 expression on MoDCs (data not shown), the following experiments were focused on the potential mechanism by which TNF-␣ and IL-10 might be involved in PD-L1 expression.
HIV-1 Tat protein induces PD-L1 expression on MoDCs through a TNF-␣-mediated mechanism. To determine whether TNF-␣ and IL-10 were involved in PD-L1 upregulation, each cytokine was selectively depleted from Tat-conditioned medium by incubation with specific neutralizing antibodies. Interestingly, when Tat-untreated MoDCs were stimulated using Tat-conditioned medium and in the presence of anti-TNF-␣-neutralizing antibodies, PD-L1 upregulation was totally abolished and reversed to a basal level (Fig. 7a) . In contrast, neutralization of IL-10 did not reverse PD-L1 upregulation on MoDCs (Fig. 7a) . As a negative control, neutralization of IFN-␥ did not affect PD-L1 upregulation (Fig. 7a) . The crucial role of Tat-induced TNF-␣ was also demonstrated in the coculture experiments using CFSE-labeled MoDCs. In this assay, the addition of anti-TNF-␣ antibodies, in contrast to the corresponding isotype, strongly inhibited PD-L1 upregulation on both Tat-treated CFSE Ϫ and Tat-untreated CFSE ϩ MoDCs (Fig. 7b and c) . In line with these results, we showed that treatment with exogenous recombinant TNF-␣ induced similar PD-L1 upregulation on MoDCs (Fig. 7d) .
All together, these results indicate that the upregulation of PD-L1 molecules induced by Tat protein on MoDCs occurs essentially through a TNF-␣-mediated mechanism.
The induction of PD-L1 expression on MoDCs by HIV-1 Tat protein involves the TLR4 pathway. Since we had recently found that HIV-1 Tat protein (i) mediates TNF-␣ production in a TLR4-dependent manner (62) and (ii) interacts physically and with high affinity with TLR4-MD2 (62), we next explored the potential association between Tat-TLR4 interaction, TNF-␣ production, and PD-L1 upregulation, both in human MoDCs and in bone marrow-derived DCs (BMDCs) from either wild-type (wt) or TLR4-KO mice. We found that stimulation of MoDCs by Tat in the presence of increasing amounts of anti-TLR4 antibodies sig- nificantly inhibited Tat-induced PD-L1 upregulation (Fig. 8a) . As in human MoDCs, Tat protein induced upregulation of PD-L1 expression in BMDCs from wt mice (Fig. 8c) . However, HIV-1 Tat protein had no effect on the BMDCs obtained from TLR4-KO mice, indicating the involvement of the TLR4 pathway (Fig. 8c) . As a control, treatment with pam3CSK4 (a TLR2 ligand) induced PD-L1 upregulation in a similar manner in BMDCs from wt or TLR4-KO mice (Fig. 8c) . In line with the previous data implicating Tat-induced TNF-␣ (Fig. 7) , we showed a direct association between Tat-induced TNF-␣ and PD-L1 upregulation ( Fig. 8b  and d) . We demonstrated that PD-L1 upregulation of human MoDCs, in the presence of anti-TLR4 antibodies, or BMDCs from wt or TLR4-KO mice by Tat were strictly associated with the production of TNF-␣ (Fig. 8b and d) . More interestingly, culturing BMDCs from TLR4-KO mice with supernatant from Tat-conditioned medium of BMDCs wt mice led to the upregulation of PD-L1 (Fig. 8c) , thus giving an additional argument for the Tatinduced TNF-␣ in the PD-L1 upregulation on the surface of DCs.
HIV-1 Tat protein-mediated PD-L1 upregulation on MoDCs functionally compromises MoDC ability to stimulate T cells.
Coculture of untreated MoDCs with CFSE-labeled autologous T cells in the presence of a suboptimal amount of anti-CD3 antibodies (10 ng/ml) led to a significant T-cell proliferation, as shown in Fig. 8c (59.2% of proliferating T cells). In contrast, pretreatment of MoDCs with synthetic or recombinant HIV-1 Tat protein strongly inhibited the capacity of Tat-treated MoDCs to activate T-cell proliferation. This result suggests that activation of the PD-L1/PD-1 T-cell coinhibitory pathway following HIV-1 Tat treatment may have compromised the functional ability of Tat-treated MoDCs to stimulate T cells ( Fig. 9d and e) . This was supported by the fact that, following treatment with HIV-1 Tat protein, the functional inhibition of T-cell proliferation was closely correlated with the upregulation of the PD-L1 coinhibitory molecule seen on MoDCs (Fig.  2a to c) . As controls, (i) no significant T-cell proliferation (less than 1%) was observed in the absence of MoDCs and anti-CD3 antibodies (Fig. 9a) , and (ii) only a basal proliferation (about 10%) was observed when T cells were stimulated by anti-CD3 in the absence of MoDCs (Fig. 9b) .
In order to ascertain the involvement of the PD-1/PD-L1 pathway in the observed inhibition of T-cell proliferation following HIV-1 Tat treatment, we tested the blocking effect of anti-PD-L1 antibodies (10 g/ml) (Fig. 9f to h) . Unexpectedly, we found that the anti-PD-L1 blockade was unable to significantly restore the capacity of Tat-treated-MoDCs to activate T-cell proliferation (Fig. 9g to h ). The absence of restoration of the capacity of MoDCs to activate T-cell proliferation, despite the interference with the PD-1/PD-L1 T-cell coinhibitory pathway, suggests the implication of other yet-to-be-determined T-cell coinhibitory pathways induced by HIV-1 Tat, such as TIM-3/Gal-9, BTLA/HVEM, and/or 2B4/CD48.
DISCUSSION
In the present study, we showed that treatment with HIV-1 Tat protein of primary myeloid DCs isolated from healthy donors or MoDCs obtained from either HIV-1-infected patients or uninfected healthy donors significantly upregulated the level of expression of PD-L1 ligand on these cells. This resulted in compromised ability of Tat-treated MoDCs to functionally stimulate T-cell proliferation. In contrast, no effect on the expression of PD-L2 ligand or PD-1 receptors was detected. The induction of PD-L1 expression on MoDCs by HIV-1 Tat protein (i) occurred in dose-and time-dependent manners, (ii) was activated by the N-terminal 1-45 fragment of Tat, (iii) was mediated by Tat-induced soluble factor(s) and thus did not require direct cell-cell contact, (iv) was totally or partially abrogated by neutralizing anti-TNF-␣ or blocking anti-TLR4 antibodies, respectively, (v) was absent in TLR4-KO mice but could be restored following incubation with Tat-conditioned medium from wt DCs, (vi) strongly impaired the capacity of MoDCs to stimulate T-cell proliferation, and (vii) was not reversed functionally by antibodies that blocked the PD-1/ PD-L1 pathway, suggesting the implication of other Tat-mediated coinhibitory pathways. To the best of our knowledge, this is the first report showing that HIV-1 Tat protein, an immunosuppressive viral factor, modulates the PD-1/PD-L1 T-cell coinhibitory pathway of antigen-presenting cells (i.e., DCs) by hijacking the TLR4 pathway.
These findings, involving Tat/TLR4/TNF-␣ pathways, suggest a novel immune evasion mechanism whereby the HIV-1 Tat may promote functional exhaustion (i.e., dysfunction) of HIV-specific CD4 ϩ and CD8 ϩ T cells in chronically infected individuals, resulting in increased virus reactivation, increased virus load, and/or fast progression toward AIDS. An understanding, at molecular and cellular levels, of the underlying mechanisms of action may offer new potential molecular targets for the development of anti-HIV-1 treatment.
In agreement with the data reported by Fanales-Belasio and coworkers (37, 71) , we found that Tat protein was able to induce the maturation of MoDCs as shown by the expression of the costimulatory molecules CD80 and CD86 and the phenotypic marker CD83. Because Tat-MoDC maturation can be blocked in the presence of anti-TNF-␣ and anti-TLR4 antibodies (data not shown), on the one hand, and can be stimulated by the N-terminal 1-45 fragment of Tat, on the other hand, our data suggest that MoDC maturation is primed by Tat action at the cell membrane level rather than following its uptake (37) . Interestingly, HTLV-1 Tax protein, the equivalent of Tat protein in HIV-1, also induced MoDC maturation (72) . Curiously, the activating effect of Tat protein seems to be counterbalanced by the action of Vpr, another HIV-1 regulatory protein, which has an antagonist effect on the maturation of DCs (73) . In contrast to our study, Izmailova and coworkers, using recombinant adenovirus Tat and HIV-1 infectious particles as a source of Tat, did not observe any effect of Tat on MoDC maturation or on the production of TNF-␣, IL-1, IL-6, and IL-12, proinflammatory cytokines that are associated with DC maturation (74) . This apparent discrepancy may be related to the absence of a sufficient amount of Tat protein following adenovirus transduction and HIV-1 infection of immature DCs. In the latter study (74) , although Tat mRNA was shown, Tat expression at the protein level was never checked.
Using a Tat-deleted mutant encoding only the N-terminal 1-45 region, we showed that this N-terminal Tat fragment continued to upregulate PD-L1 on MoDCs in a manner similar to that of the whole Tat protein. However, because the N-terminal 1-45 fragment does not have the capacity to trans activate HIV-1 LTR, we conclude that the upregulation of PD-L1 mediated by Tat is independent of the two crucial basic and cysteine domains essential for Tat trans activation activity. This conclusion is also in agreement with the inability of this N-terminal 1-45 fragment to be taken up by cells, because it lacks the 49 -57 basic domain necessary for the cellular uptake of Tat protein. All together, these results rule out the possibility that Tat-mediated upregulation of PD-L1 on MoDCs occurred through an intracellular mechanism. The hypothesis of a direct action of Tat on the cell surface was further excluded, because Tat-conditioned medium was sufficient to upregulate PD-L1 on MoDCs, clearly showing that physical contact between Tat and MoDCs is not necessary for PD-L1 upregulation. To double-check the indirect hypothesis, we explored the potential implication of Tat-induced cytokines in the upregulation of PD-L1 on MoDCs in a kinetic study. Among the potential cytokines released in MoDC supernatant 6 h after Tat treatment, only TNF-␣ was able to induce PD-L1 upregulation on MoDCs. The indirect effect of this cytokine was ascertained by the capacity of anti-TNF-␣ antibodies to interfere with PD-L1 upregulation induced by Tat protein. The underlying mechanisms of how TNF-␣ contributed to PD-L1 upregulation mediated by Tat are beyond the scope of the present study and will be the subject of a future report. In HIV-1-infected fast progressors, an increase of PD-L1 has been observed on MoDCs. This increase seems to be directly associated with an increase in the viral load, a decrease of CD4 ϩ T-cell counts, and a fast progression to AIDS (23) . In contrast, a nonsignificant upregulation of PD-L1 has been observed on MoDCs from HIV-1 nonprogressors (23). These observations were also confirmed in the SIV/macaque model in which an increase of PD-L1 on plasmacytoid and myeloid DCs and of PD-1 on CD4
ϩ and CD8 ϩ T cells was associated with higher loads and fast progression to disease (75) . More interestingly, it has been shown that PD-L1-and PD-1-positive cells colocalized within the same sites of infection, suggesting a functional role of PD-1-PD-L1 interaction in the physiopathology of SIV infection (75) . A subsequent in vivo study has shown that treatment of SIV-infected macaques with anti-PD-1-blocking antibodies was associated with (i) an expansion of anti-SIV CD8 ϩ T cells, (ii) an enhancement of antibodies against SIV envelope glycoproteins, (iii) a reduction of plasmatic SIV viral load, and (iv) longer survival (32) . In a more recent study, the same group reported that the PD-1 blockade, even during chronic infection, was also accompanied by a functional repair of the gastrointestinal tract barrier, as shown by the diminution of LPS in the plasma, and a reduction of hyperimmune activation, as shown by the diminution of the expression of type I IFN-stimulated genes (ISGs) (30) .
The present study extends the above-described findings by showing that HIV-1 Tat protein was behind the upregulation of the PD-L1 molecule on MoDCs. However, the finding that the PD-1/PD-L1 T-cell coinhibitory pathway is affected by HIV-1 Tat does not rule out the possibility that other coinhibitory pathways are affected by Tat immunosuppressive viral protein. This is supported by our results showing that blockade of the PD-1/PD-L1 pathway was not sufficient to reverse the T-cell stimulation function of Tat-treated DC. The absence of restoration of the capacity of MoDCs to activate T-cell proliferation, despite the interference with the PD-1/PD-L1 coinhibitory pathway, suggests an implication of other yet-to-be-determined T-cell coinhibitory pathways, such as TIM-3/Gal-9, BTLA/HVEM, and/or 2B4/CD48 (76, 77) , or other Tat-induced immunosuppressive factors that remain to be clearly identified. Accordingly, the effect of Tat on the potential modulation of other T-cell coinhibitory pathways and other immunosuppressive factors is currently being evaluated in our laboratory. Our group has previously shown that HIV-1 Tat protein is also able to stimulate the expression of IL-10 (33, 68) and IDO (78) , two factors known for their highly immunosuppressive activities.
The effect of the blockade of the PD-1/PD-L1 pathway in the course of HIV-1 infection has also been confirmed in HIV-1-infected humanized BALB/c-Rag2 Ϫ/Ϫ ␥c Ϫ/Ϫ (Rag-hum) mice (79) . This model was first validated by showing that infection of humanized Rag-hum mice with the R5 tropic HIV-1-BaL isolate led to an increase of viral load in the plasma, accompanied by CD4 ϩ T-cell depletion and an enhancement of PD-1 expression on T cells (79) . As expected, treatment of HIV-1-infected humanized mice with anti-PD-L1 antibodies significantly restored T-cell function, elevated CD4 ϩ T-cell count, and resulted in a plasmatic reduction of viral load (79) . To the best of our knowledge, neither anti-PD-1 nor anti-PD-L1 treatment has ever been tested in clinical trials in HIV-1-infected human patients. Nevertheless, a treatment with anti-PD-1-blocking antibodies (lambrolizumab) has recently been tested in phases II and III in human patients with advanced melanoma (80) . The results were promising, with significant tumor regression and only minor secondary effects (80) . This obviously points to the possibility of a new treatment in the HIV setting.
In summary, to the best of our knowledge, the results presented in this study show, for the first time, that treatment of human MoDCs with HIV-1 Tat protein significantly upregulates the level of expression of PD-L1 ligand, which results in compromised ability of these professional APCs to functionally stimulate T cells. This effect is activated by the N-terminal Tat 1-45 domain and appears to be mediated by a yet-to-be-determined TNF-␣-and TLR4-dependent mechanism. While HIV-1 Tat upregulated PD-L1 and strongly impaired the capacity of MoDCs to stimulate T-cell proliferation, this effect was not functionally reversed by antibodies blocking the PD-1/PD-L1 pathway. This suggests the implication of other Tat-mediated coinhibitory pathways, including TIM-3/Gal-9, CTLA4/B7-1/2, BTLA/HVEM, 2B4/CD48, CD160/HVEM, and LAG3/MHCII.
Since functional CD4 ϩ and CD8 ϩ T cells appear to be important effectors of HIV-1 protective immunity, the present findings offer new potential molecular targets for the development of anti-HIV-1 treatment that would reverse the apparent dysfunction (exhaustion) of HIV-specific T cells during chronic infection. A combination of blockade of the PD-1/PD-L1 T-cell coinhibitory pathway in combination with therapeutic vaccination, including oxidized Tat protein as the immunogen, may hold great therapeutic promise.
